EMEA-002464-PIP01-18

Key facts

Active substance
Human immunoglobulin (Ig) G4-variant monoclonal antibody that binds and neutralizes soluble human
Therapeutic area
Dermatology
Decision number
P/0275/2019
PIP number
EMEA-002464-PIP01-18
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of atopic dermatitis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Eli Lilly and Company

E-mail: eu_paediatric@lilly.com 
Tel. +44 (0)1276 483000

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating